Renin-angiotensin system (RAS) inhibitors (RASi)—widely prescribed for the treatment of
cardiovascular diseases—have considerable potential in oncology. The RAS plays a crucial …

Emerging evidence supports that cancer incidence is increased in patients with
cardiovascular (CV) disease and heart failure (HF), and patients with HF frequently die from …

In ovarian cancer patients, tumor fibrosis and angiotensin-driven fibrogenic signaling have
been shown to inversely correlate with survival. We sought to enhance drug delivery and …

For cancers to develop, sustain and spread, the appropriation of key homeostatic
physiological systems that influence cell growth, migration and death, as well as …

Although VEGF-targeted therapies are showing promise, new angiogenesis targets are
needed to make additional gains. Here, we show that increased Zeste homolog 2 (EZH2) …

The renin–angiotensin system (RAS) has long been described in the field of cardiovascular
physiology as the main player in blood pressure homeostasis. However, other effects have …

It is now apparent that regulation of blood vessel growth contributes to the classical actions
of hormones on development, growth, and reproduction. Endothelial cells are ideally …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown diverse life-
threatening effects, most of which are considered short-term. In addition to its short-term …

Multiple sites of phosphorylation on human estrogen receptor a (ERa) have been identified
by a variety of methodologies. Now with the emerging availability of phospho-site-specific …

The renin-angiotensin system (RAS) is well known as regulator of electrolytes and blood
pressure. Besides this function, there are numerous studies supporting the idea of a local …